Del Re et al. reported that mRNA expression of thymidine kinase 1 (TK1), CDK4, 6 and 9 in plasma-derived vesicles of ER+/HER2-advanced breast cancer patients can predict sensitivity to CDK inhibitor treatments. Here, ERBB2 is linked to breast cancer.